Micturin and Torsades de Pointes

Pharmacovigilance: Second Edition

Volumn , Issue , 2007, Pages 105-108

  Wild, Richard N ^a  

^a Arakis Ltd   (United Kingdom)

Author keywords

Adverse drug event (ADE) requirements; Committee on Safety of Medicines (CSM); Micturin and torsades de pointes (TP); TP and prior QT interval lengthening in ECG; VAMP and PEM databases

Indexed keywords

EID: 84889317451     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470059210.ch9     Document Type: Chapter

References (19)

1. Andersson K-E, Ekström B, Mattiasson A (1988) Actions of terodiline, its isomers and main metabolite on isolated detrusor muscle from rabbit and man. Acta Pharmacol Toxicol 63: 390-5.
2. Asscher AW (1991) Terodiline (Micturin) and adverse cardiac events. Committee on Safety of Medicines (letter).
3. Ben-David J, Zipes DP (1993) Torsades de pointes and proarrhythmia. Lancet 341: 1578-82.
4. Connolly MJ, Astridge PS, White EG, Morley CA, Campbell Cowan J (1991) Torsades de pointes ventricular tachycardia and terodiline. Lancet 338: 344-5.
5. Desertenne F (1966) La tachycardie ventriculaire á deux foyers opposés variable. Archives des Maladies du Coeur et des Vaisseaux 59: 263-72.
6. Hall GC, Chukwujindu J, Richardson J, Lis Y, Wild RN (1993) Micturin (terodiline hydrochloride), torsades de pointe and other arrhythmias-a study using the VAMP database. Pharmacoepidemiol Drug Saf 2: 127-32.
7. Hallén B, Bogentoft S, Sandquist S, Stromberg S, Setterberg G, Ryd-Kjellen E (1989) Tolerability and steady state pharmacokinetics of terodiline and its main metabolites in elderly patients with urinary incontinence. Eur J Clin Pharmacol 36: 487-93.
8. Hartigan-Go K, Bateman N, Daly AK, Thomas SHL (1996) Stereoselective cardiotoxic effects of terodiline. Clin Pharmacol Ther 60: 89-98.
9. Hussain RM, Hartigan-Go K, Thomas SHL, Ford GA (1996) Effect of oxybutinin on the QTc interval in elderly patients with urinary incontinence. Br J Clin Pharmacol 41: 73-5.
10. Husted S, Andersson K-E, Sommer L, Ostergaard JR (1980) Anticholinergic and calcium antagonistic effects of terodiline in rabbit urinary bladder. cta Pharmacologica et Toxicologica (Copenhagen) (Suppl 1) 46: 20-30.
11. Inman W, Clarke J, Wilton L, Pearce G, Veldhuis GJ (1993) PEM Report Number 2. Terodiline. Pharmacoepidemiol Drug Saf 2: 287-319.
12. Langtry HD, McTavish D (1990) Terodiline: a review of its pharmacological properties and therapeutic use in the treatment of urinary incontinence. Drugs 40: 748-61.
13. McCleod AA, Thorogood S, Barnett S (1991) Torsades de pointes complicating treatment with terodiline. BMJ 302: 1469.
14. Shuba LM, Kasamaki Y, Jones SE, Ogura T, McCullough JR, McDonald TF (1999) Action potentials, contraction, and membrane currents in guinea pig ventricular preparations treated with the antispasmodic agent terodiline. J Pharmacol Exp Ther 290: 1417-26.
15. Stewart DA, Taylor J, Ghosh S, Macphee GJA, Abdullah I, McLenachan, Stott DJ (1992) Terodiline causes polymorphic ventricular tachycardia due to reduced heart rate and prolongation of QT interval. Eur J Clin Pharmacol 42: 577-80.
16. Stratman HS, Kennedy HL (1987) Torsades de pointes associated with drugs and toxins: recognition and management. Am Heart J 113: 1470-82.
17. Thomas SHL, Higham PD, Hartigan-Go K, Kamali F, Wood P, Campbell RWF, Ford GA (1995) Concentration dependent cardiotoxicity of terodiline in patients treated for urinary incontinence. Br Heart J 74: 53-6.
18. Wild RN (1992) Micturin and torsades de pointe-experience of a post-marketing alert. Pharmacoepidemiol Drug Saf 1: 147-50.
19. Yap YG, Camm J (2000) Risk of torsades de pointes with non-cardiac drugs. BMJ 320: 1158-9.